GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » LT-Debt-to-Total-Asset

NKGen Biotech (NKGen Biotech) LT-Debt-to-Total-Asset : 0.64 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NKGen Biotech's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.64.

NKGen Biotech's long-term debt to total assets ratio increased from Dec. 2022 (0.00) to Mar. 2024 (0.64). It may suggest that NKGen Biotech is progressively becoming more dependent on debt to grow their business.

NKGen Biotech LT-Debt-to-Total-Asset Historical Data

The historical data trend for NKGen Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech LT-Debt-to-Total-Asset Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
0.02 - 0.60

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial - - 0.58 0.60 0.64

NKGen Biotech LT-Debt-to-Total-Asset Calculation

NKGen Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=9.93/16.481
=

NKGen Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=10.495/16.316
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech  (NAS:NKGN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

NKGen Biotech LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.